22 January 2026
: Case report 
Management of Bartholin’s Gland Carcinoma in a Perimenopausal Woman: A Case Report
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Patient complains / malpractice, Unexpected drug reaction, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Przemysław Borawski ABCDE 1*, Robert Kulhawik
B 2, Dariusz Boroń C 3,4,5, Tomasz Sirek E 3,6,7, Kacper Boroń F 7, Piotr Ossowski E 3, Marcin Opławski F 4,8, Beniamin Oskar Grabarek E 3,9
DOI: 10.12659/AJCR.951359
Am J Case Rep 2026; 27:e951359
Table 2 Changes in CEA and CA 19–9 levels during the observation period.
| Time* | Material | CEA (ng/mL) | P<0.05*** | CA 19–9 (U/mL) | P<0.05*** | ||||
|---|---|---|---|---|---|---|---|---|---|
| Median** | Q1 | Q3 | Median** | Q1 | Q3 | ||||
| 0 | Whole blood | 123.87 | 123.37 | 123.95 | 0.0410.000,,,,,,0.0390.0020.0415A | 425.5 | 424.25 | 426.75 | 0.0380.000,,,,,,0.0310.0180.04310.023A |
| Cancer tissue | 154.08 | 152.09 | 155.7 | 418.09 | 412.19 | 421.03 | |||
| 1 | Whole blood | 118.09 | 116.36 | 120.6 | 418 | 417.75 | 419.5 | ||
| 2 | Whole blood | 175.88 | 175.38 | 175.88 | 444 | 443.75 | 449 | ||
| 3 | Whole blood | 32.0 | 31.99 | 32.01 | 213 | 212.5 | 214 | ||
| 4 | Whole blood | 4.44 | 4.38 | 4.44 | 63 | 62.75 | 63.5 | ||
| 5 | Whole blood | 2.18 | 1.18 | 2.2 | 11 | 10.75 | 11 | ||
| * Time 0, before lesion excision; time 1, before curettage of the uterine cavity and cervical canal, time 2, before radical lesion excision; time 3, before chemotherapy; time 4, before radiotherapy; time 5, 6 months after treatment completion. ** Median, Q1, and Q3 values for each time point represent technical replicates from the same sample. *** Statistically significant differences in tumor marker concentrations in whole blood at different time points, as determined by analysis of variance with Friedman’s post hoc test: A – 2 vs 0; B – 3 vs 0; C – 4 vs 0; D – 5 vs 0; E – 2 vs 1; F – 3 vs 1; G – 4 vs 1; H – 5 vs 1; I – 3 vs 4; J – 3 vs 5; K – 4 vs 5; L – Statistically significant differences in tumor marker concentrations, as determined by the Mann-Whitney U test. CA 19–9 – cancer antigen 19–9; CEA – carcinoembryonic antigen; Q1 – first quartile; Q3 – third quartile. | |||||||||